http://rdf.ncbi.nlm.nih.gov/pubchem/patent/NZ-627824-A

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_910eee9a3e47364b7cf279ffa319673b
classificationCPCAdditional http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2300-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2121-00
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-52
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-505
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-18
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-513
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0053
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-675
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4985
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0019
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0014
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-536
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-5365
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-18
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4375
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-5383
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A01N43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4985
filingDate 2011-01-24-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_69e58ecfbea46000822390882e766ae7
publicationDate 2016-02-26-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber NZ-627824-A
titleOfInvention Antiviral combinations involving (4r,12as)-n-[(2,4-difluorophenyl)methyl]-3,4,6,8,12,12a-hexahydro-7-hydroxy-4-methyl-6,8-dioxo-2hpyrido[1’,2’:4,5]pyrazino[2,1-b][1,3]oxazine-9-carboxamide
abstract Disclosed are combinations of the compound of formula I (4R,12aS)-N-[(2,4-difluorophenyl)methyl]-3,4,6,8,12,12a-hexahydro-7-hydroxy-4-methyl-6,8-dioxo-2H-pyrido[1’,2’:4,5]pyrazino[2,1-b][1,3]oxazine-9-carboxamide (also known as dolutegravir and GSK1349572) and rilpivirine (TMC-278) or a pharmaceutically acceptable salt thereof. Also disclosed is the use of the combination in the manufacture of a medicament for the treatment of HIV infection.
priorityDate 2010-01-27-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID54726191
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419475605
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419510094
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID458394670
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID6451164
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID458393636

Total number of triples: 38.